InnoCare Pharma Limited (HKG:9969)

Market Cap	21.33B
Revenue (ttm)	1.07B
Net Income (ttm)	-468.91M
Shares Out	1.76B
EPS (ttm)	-0.28
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,259,397
Average Volume	14,876,407
Open	10.58
Previous Close	10.36
Day's Range	10.18 - 10.82
52-Week Range	4.22 - 10.96
Beta	1.03
RSI	66.36
Earnings Date	Mar 28, 2025

About InnoCare Pharma

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom’s macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thro...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 1,089
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9969

Financial Performance

In 2024, InnoCare Pharma's revenue was 1.01 billion, an increase of 36.68% compared to the previous year's 738.54 million. Losses were -440.63 million, -30.20% less than in 2023.

Financial numbers in CNY